Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer ; volume:11 ; number:1 ; day:18 ; month:3 ; year:2021 ; pages:1-7 ; date:12.2021
Scientific reports ; 11, Heft 1 (18.3.2021), 1-7, 12.2021
- Creator
-
Parikh, Mamta
Liu, Chengfei
Wu, Chun-Yi
Evans, Christopher P.
Dall’Era, Marc
Robles, Daniel
Lara, Primo N.
Agarwal, Neeraj
Gao, Allen C.
Pan, Chong-Xian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-021-85969-x
- URN
-
urn:nbn:de:101:1-2022111209232812606083
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Parikh, Mamta
- Liu, Chengfei
- Wu, Chun-Yi
- Evans, Christopher P.
- Dall’Era, Marc
- Robles, Daniel
- Lara, Primo N.
- Agarwal, Neeraj
- Gao, Allen C.
- Pan, Chong-Xian
- SpringerLink (Online service)
Other Objects (12)
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment